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1. Introduction 
 
1.1. Introduction into neurogenetics 
 
The field of neurogenetics emerged from advances made in molecular 
biology, genetics and a desire to understand the link between genes, behavior, the 
brain, and neurological disorders and diseases. The field started to expand in the 
1960s through the research of Seymour Benzer, considered by some to be the 
father of neurogenetics (Benzer, 1967). His pioneering work with Drosophila 
helped to elucidate the link between circadian rhythms and genes, which lead to 
further investigations into other behavior traits (Konopka and Benzer, 1971).  
Early analysis relied on statistical interpretation through processes such as 
LOD (logarithm of odds) scores of pedigrees and other observational methods 
such as affected sib-pairs, which looks at phenotype and IBD (identity by descent) 
configuration. Many of the disorders studied on early including Alzheimer’s, 
Huntington's and amyotrophic lateral sclerosis are still at the center of much 
research to this day (Gershon and Goldin, 1987).  
By the late 1980s new advances in genetics such as recombinant DNA 
technology and reverse genetics allowed the broader use of DNA polymorphisms 
to test for linkage between DNA and gene defects (Tanzi, 1991). By the 1990s 
ever advancing technology had made genetic analysis more feasible and available 
(Simon-Sanchez, 2008). This decade saw a marked increase in identifying the 
specific role of genes and genetic variations played in relation to neurological 
disorders (Gajda et al., 2013; Horváth et al., 2013).  
Currently there are several neurogenetic disorders, in which causative 
treatment do not exist. However, neurogenetics is an emerging field that might 
yield a causative connection and provide the basis for the development of future 
novel therapeutic modalities.  
In this study, I have summarized the genetic investigations and the 
difficulties of the genetic counselling on family planning in three neurogenetic 
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disorders – Angelman syndrome, nemaline myopathy and hyperekplexia – 
presented in three Hungarian families.  
 
1.2. Angelman syndrome 
 
Angelman syndrome (OMIM 105830) is a rare neurodevelopmental 
disorder. Angelman syndrome has been reported throughout the world among 
different ethnic groups. Its prevalence is estimated between 1:10000 and 1:20000 
(Petersen et al., 1995; Steffenburg et al., 1996; Vercesi et al., 1999).  
 
1.2.1. Clinical symptoms 
 
Angelman syndrome is characterized by severe mental and physical delay, 
limited speech, fine tremor, ataxia, excessive mouthing behavior, fascination with 
water, jerky limb movements, seizures, craniofacial abnormalities and unusually 
happy sociable behavior characterized by frequent episodes of inappropriate 
smiling (Clayton-Smith et al., 2003; Williams et al., 2006). The frequency of the 
different symptoms is described in Table 1 (Williams et al., 2006). 
 
Frequency Symptoms 
Consistent (100%) 
developmental delay, speech impairment, 
movement or balance disorder, behavioral 
uniqueness 
Frequent (>80%) 
delayed growth in head circumference, seizures, 
abnormal EEG 
Associated (20–80%) 
strabismus, hypopigmented skin and eyes, tongue 
thrusting, hyperactive tendon reflexes, feeding 
problems during infancy, flexed arms during 
walking, prominent mandible, increased sensitivity 
to heat, wide mouth, wide-spaced teeth, sleep 
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disturbance, frequent drooling, protruding tongue, 
attraction to water, excessive chewing behaviors, 
flat back of head, smooth palms 
 
Table 1. The frequency of the symptoms in Angelman syndrome (Williams et al., 
2006). 
 
1.2.2. Genetic background 
 
Seventy percent of Angelman syndrome cases investigated with molecular 
genetics methods are the result of a small deletion in the 11-13 region of the 
maternal chromosome 15. A deletion in the same region of the paternal 
chromosome 15 results in the sister disorder Prader-Willi syndrome. Expression of 
the genes in the 11-13 region is regulated by the imprinting center, which 
differentially silences the paternal copy of the ubiquitin protein ligase E3A 
(UBE3A) gene in the hippocampus and in the cerebellum. 
 
 
 
Figure 1. Schematic drawing of the different mechanisms resulting in Angelman 
syndrome (Williams et al., 2006). 
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Other genetic abnormalities resulting in Angelman syndrome include 
uniparental disomy (UPD; 5%), mutations of the imprinting center (5%), 
mutations of the UBE3A gene (10%), and other mechanisms (10%; Poyatos et al., 
2002; Tan et al., 2011; Figure 1.). 
 
1.3. Nemaline myopathy 
 
Nemaline myopathy belongs to the group of congenital myopathies, which 
are a group of genetic muscle disorders with clinical, pathological and molecular 
heterogeneity (Nance et al., 2012). Nemaline myopathy is a pathologically well-
defined subgroup of congenital myopathies characterized by the presence of rod-
like structures in the muscle fibers (Wallgren-Petterson et al., 2011). Annual 
incidence has been estimated at 1:50000 live births in a Finnish study but the 
disease is more common in the Amish community (Johnston et al., 2000).  
 
1.3.1. Clinical symptoms 
 
The nemaline myopathy presents a wide range of clinical variability and 
severity, although generalized hypotonia, muscle weakness, feeding difficulties 
and delay of motor milestones are almost always present (Wallgren-Petterson et 
al., 2011). Its most common form is nemaline myopathy type 2, which is 
characterized by early onset muscle weakness, which is most pronounced in the 
axial muscles and proximal limb-girdles. Weakness in facial and bulbar muscles 
commonly results in dysarthria (Wallgren-Petterson et al., 1989). The course of 
the disease is non-progressive or slowly progressive and life-expectancy depends 
on the severity of respiratory-muscle weakness. Mechanical ventilation is 
necessary for some patients and orthopedic complications are frequent (Wallgren-
Petterson et al., 1999). Mental development and intelligence are typically within 
the normal range (Wallgren-Petterson et al., 1999). 
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1.3.2. Genetic background 
 
All molecularly characterized forms of nemaline myopathy are autosomal, 
but inheritance can be recessive or dominant, and singleton cases may arise from 
de novo dominant mutations (North et al., 2011). ) Labeit et al. in 2011 described 
six genes that have been linked to this condition: α-tropomyosin (TPM3)(1q21.3), 
nebulin (NEB)(2q23.3), skeletal muscle α-actin (ACTA1)(1q42.13), β-tropomyosin 
(TPM2)(9p13.3), muscle troponin T1 (TNNT1)(19q13.42), cofilin-2 
(CFL2)(14q13.1). Two recently identified genes with mutations causing nemaline 
myopathies are‘‘Kelch-repeat and BTB (POZ) domain containing 13”  
(KBTBD13)(15q22.31), and and kelch-like family member 40 (KLHL40) (3p22.1)   
Type Gene OMIM ID Number 
Nemaline myopathy type 1 TPM3(1q23.3) 609284(AR/AD) 
Nemaline myopathy type 2 NEB(2q23.3) 256030(AR) 
Nemaline myopathy type 3 ACTA1(1q42.13) 161800 (AR/AD) 
Nemaline myopathy type 4 TPM2(9p13.3) 609285(AD) 
Nemaline myopathy type 5 TNNT1(19q13.42) 605355(AR) 
Nemaline myopathy type 6 KBTBD13(15q22.31) 609273 (AD) 
Nemaline myopathy type 7 CFL2(14q13.1) 610687(AR) 
Nemaline myopathy type 8 KLHL40(3p22.1) 615348 (AR) 
 
Table 2. Summary of the causative genes identified in the background of the 
different types of nemaline myopathy  
 
Its most common form, the nemaline myopathy type 2 is a rare autosomal 
recessive condition and develops as the consequence of mutations in the NEB gene 
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(OMIM 256030). The NEB gene is located at 2q22 and encodes nebulin, which is 
an actin-binding protein (McElhinny et al., 2003). It binds approximately 200 actin 
monomers (McElhinny et al., 2003). Its length is proportional to thin filament 
length and it acts as a thin filament regulator and influences thin filament length 
during sarcomere assembly (McElhinny et al., 2003).  
 
1.4. Hereditary hyperekplexia 
 
Hereditary hyperekplexia also known as Stiff baby syndrome 
(ORPHA3197) is an early-onset neurological disorder characterized by excessive 
startle responses with violent jerking to sudden, unexpected auditory or tactile 
stimuli (Kirstein and Silfverskiold, 1958; Ryan et al., 1992). The exact prevalence 
of hereditary hyperekplexia is unknown. This condition has been identified in 
more than 70 families worldwide (Lapunzina et al., 2003). 
 
1.4.1. Clinical symptoms 
 
Hereditary hyperekplexia usually develops shortly after birth: neonates 
have prolonged periods of stiffness, clenching fists and attacks of a high-frequency 
trembling (Kirstein and Silfverskiold, 1958; Ryan et al., 1992). Hereditary 
hyperekplexia can have severe consequences such as sudden infant death due to 
laryngospasm and cardiorespiratory failure (Ryan et al., 1992). The symptoms 
tend to resolve after infancy; however adults may have increased startle-induced 
falls or nocturnal muscle jerks (Ryan et al., 1992). 
 
1.4.2. Genetic background 
 
Hereditary hyperekplexia has a heterogeneous genetic background (Harvey 
et al., 2008; James et al., 2012). Different mutations in several genes involved in 
glycinergic neurotransmission can lead to hereditary hyperekplexia, and the 
disease exhibits both autosomal recessive and dominant inheritance (Harvey et al., 
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2008; James et al., 2012). Mutations in the glycine receptor alpha 1 subunit gene 
(GLRA1) result in hereditary hyperekplexia type 1 (OMIM149400) and occur in 
about 30% of the cases (Rees et al., 1994). Mutations in other genes such as the 
glycine receptor beta subunit gene (GLRB; OMIM614619; Al-Owain et al., 
2012), the glycine transporter solute carrier family 6 member 5 gene (SLC6A5; 
OMIM614618; Rees et al., 2006), the glycine receptor locator gephyrin gene 
(GPHN; OMIM603930; Reiss et al., 2001) and the postsynaptic glycine enhancer 
collybistin gene (ARHGEF9; OMIM300429; Harvey et al., 2004) have also been 
associated with this clinical condition. 
 
Type Gene 
OMIM ID 
Number 
Hereditary hyperekplexia type 1 GLRA1(5q33.1) 149400(AD/AR) 
Hereditary hyperekplexia type 2 GLRB(4q32.1) 614619(AR) 
Hereditary hyperekplexia type 3 SLC6A5(11p15.1) 614618(AD/AR) 
Molybdenum cofactor deficiency 
type C 
GPHN(14q23.3) 603930(AD) 
Early infantile epileptic 
encephalopathy type 8 
ARHGEF9 
(Xq11.1-11.2) 
300429(XR) 
 
Table 3. Summary of the causative genes identified in the background of the 
different types of hereditary hyperekplexia (http://www.omim.org/entry/149400). 
 
The most common form of hereditary hyperekplexia is a rare autosomal 
dominant or autosomal recessive condition and develops as the consequence of 
mutations in the GLRA1 gene. The GLRA1 gene is located at 5q32 and encodes the 
alpha-1 subunit of the glycine receptor, a ligand-gated chloride channel 
(Grenningloh et al., 1990). This inhibitory glycine receptor mediates postsynaptic 
inhibition in the spinal cord and other regions of the central nervous system 
(Grenningloh et al., 1990).  
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1.5 Aims 
 
The field of neurogenetics emerged in the 1960s from advances made in 
molecular biology, genetics and a desire to understand the link between genes, 
behavior, the brain, and neurological disorders and diseases. Due to the discoveries 
of the Human Genome Project and the recent technical and methodological 
developments in genetics and genomics, this decade saw a marked increase in 
identifying the specific role of genes and genetic variations relating to neurological 
disorders (Gajda et al., 2013; Horváth et al., 2013).  
In this study, my aim was to summarize the genetic investigations and the 
difficulties of the genetic counselling on family planning in Hungarian families 
affected by three different neurogenetic disorders: My aim was to investigate a 16-
month-old Hungarian child, in whom the genetic analysis and the clinical 
symptoms revealed a rare type of Angelman syndrome and to investigate the 
parents and help the family in further family planning.  
It was also among my goals to investigate the genetic background in a 4-
year-old Hungarian boy presenting with the clinical and histological findings of 
nemaline myopathy type 2. When I started my investigations the mother of the 
affected child was already expecting her next baby therefore I aimed to investigate 
the available family members and help the parents with prenatal genetic diagnostic 
investigations.    
I have also aimed to identify the causative genetic abnormalities in a 1-
year-old Hungarian child with the clinical symptoms of hereditary hyperekplexia 
type 1 and to investigate the parents and help the family in further family planning.  
My investigations have great importance for the affected families since 
they help family planning. Hopefully, these findings might also provide the basis 
of future studies for the development of novel therapeutic modalities in 
neurogenetic disorders.  
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2. Patients and methods 
 
2.1. Patients 
 
2.1.1. Patient affected by Angelman syndrome 
 
A 16-month-old Hungarian child was referred to our genetic counseling 
unit with delayed psychomotor and speech development and dysmorphic features, 
including wide nasal bridge, low set ears, thick lips, wide mouth with protuberant 
tongue (Figure 2.). Tongue thrusts were observed. Head circumference was 47cm 
(25 percentile).  
The affected child was born at term after an uneventful first pregnancy with 
normal weight (3260 g) and head circumference (33 cm). The Apgar scores were 
9, 10 and 10 at 1, 5 and 10 minutes, respectively. No signs of decreased fetal 
movement, neonatal hypotonia or feeding difficulties were reported. 
 
 
Figure 2. Clinical picture of the patient with Angelman syndrome (Horváth et al., 
2013). 
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2.1.1.1. Family of the patient affected by Angelman syndrome 
 
The investigated patient was the only affected family member, all the 
others including the patient’s parents were healthy and showed no symptoms of 
the Angelman syndrome (Figure 3.). 
 
 
 
Figure 3. Pedigree of the Hungarian family affected by Angelman syndrome 
(Horváth et al., 2013). 
 
2.1.2. Patient affected by nemaline myopathy type 2 
 
The patient, a boy was born at term from the fourth uneventful pregnancy. 
Birth weight was 3450 g and Apgar scores were 9 and 10 at 5 and 10 minutes, 
respectively. Floppiness and weak cry were noticed in the neonatal period. 
Generalized hypotonia, weakness and delayed acquisition of motor milestones 
were observed in early childhood. He began to walk with support at the age of 2 
years. Deep tendon reflexes were reduced. There was no fasciculation in the 
tongue. He suffered also from recurrent respiratory tract infections. The serum 
creatine kinase activity was normal. The optic fundus and brain MRI were also 
normal  Tandem mass spectrometry and urine gas chromatography screening 
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showed no evidence of inborn error of metabolism. Nerve conduction velocity was 
normal, and electromyography did not show any abnormalities.  
The possibility of a congenital myopathy emerged and muscle biopsy was 
performed at the age of 4 years. Severe respiratory tract infection and pneumonia 
led to respiratory failure later requiring tracheostomy and mechanical ventilation. 
His condition improved, however he needs ventilatory support during sleep. 
Cardiological examination did not show any abnormalities. The patient’s cognitive 
abilities were appropriate for his age. 
 
2.1.2.1. Muscle biopsy of the patient with nemaline myopathy 
 
The histological work up of the muscle biopsy tissue followed standard 
procedures. The majority of the muscle fibers were hypoplastic or atrophic with 
large variation in fiber size. Fiber necrosis, regeneration, phagocytosis, or 
inflammatory cell infiltration were not noted. Gomori’s trichrome technique 
detected prominent red-stained inclusion bodies in the fibers with variation in 
number and distribution. Gomori trichrome stained sections showed rod-shaped 
particles in the fibers (Figure 4a).  
 
 
 
Figure 4. Gomori trichrome stain (a) and electronmicroscopy investigation (b) of 
the patient with nemaline myopathy type 2 (Gajda et al., 2013). 
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Electronmicroscopy revealed that the rods appeared as electron-dense 
structures localized mainly along the thickened Z-lines (Figure 4b). These rod-
shaped particles were identified as nemaline rods/bodies, and these findings were 
consistent with the diagnosis of  nemaline myopathy. 
 
2.1.2.2. Family of the patient affected by nemaline myopathy 
 
The patient’s parents and his three siblings - one brother and two sisters – 
showed no symptoms of nemaline myopathy type 2 (Figure 5.). 
 
 
Figure 5. Pedigree of the Hungarian family affected by nemaline myopathy type 2 
(Gajda et al., 2013). 
 
2.1.3. Patient affected by hereditary hyperekplexia 
 
A male neonate was born on term at the 40
th
 week of gestation by cesarean 
section delivery after an uneventful pregnancy. His birth weight was 3990 g and 
Apgar score was 9/10. At day 1 post-term, he developed pneumothorax and was 
admitted to the perinatal intensive care unit for extra oxygen and parenteral fluid 
therapy. At day 4 post-term, abnormal movements, stiffness of the muscles and 
convulsions were observed, and phenobarbital therapy was initiated. Neurological 
investigation suggested developmental disturbances of the basal moving circle. At 
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day 11 post-term, he was hospitalized in a developmental neurology ward. 
Examination did not identify hypoxia-induced regulatory abnormalities. The 
observed recurrent muscular hypertonia was attributed to a suspected ion channel 
disorder and carbamazepine therapy was initiated.     
 
2.1.3.1. Family of the patient affected by hereditary hyperekplexia 
 
The investigated patient was the only affected family member, the patient’s 
parents were healthy and showed no symptoms of the hereditary hyperekplexia 
(Figure 6.). 
 
 
Figure 6. Pedigree of the Hungarian family affected by hereditary hyperekplexia. 
 
2.2. Methods 
 
Written informed consents were obtained from all investigated individuals 
during pre-test genetic counselling before molecular cytogenetic and genetic 
investigations were carried out. The investigated individuals were informed about 
the results of the investigations during post-test genetic counselling. The study was 
conducted according to the Principles of the Declaration of Helsinki.   
 
 
 
I/1 I/2 
II/1 II/2 
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2.2.1. Cytogenetic analysis of chromosomes 
 
For cytogenetic analysis whole peripheral blood samples of the 
investigated individuals were used. Blood samples were collected in sterile tubes 
containing sodium heparin. Whole blood leucocytes separated from red blood cells 
were placed in culture medium supplemented with serum and antibiotics. Then, 
mitogen was added to induce mitosis. The cultures were incubated at 37ºC for 72 
hours in an incubator. The cultures have to be shaken at least twice daily which 
significantly increases mitosis. Then, colchicine was added to the cultures few 
hours before harvesting to arrest the cells in metaphase. After 72 hours, the 
centrifuge tubes, in which the cultures were set were centrifuged at 1000 rpm for 
10 minutes. Then, the supernatant was discarded and the cells were gently 
suspended in freshly prepared potassium chloride solution and incubated in an 
incubator at 37ºC for about 30 minutes. Then centrifugation was repeated followed 
by addition of 3:1 methanol and acetic acid, which acted as a fixative. The fixative 
were washed out to obtain a clear cell button at the bottom of the tube. Then, the 
chromosomes were prepared by dropping the cell suspension on a clean, grease 
free slide, where, the drop spread out and the chromosomes got fixed on the slides. 
Once the slides were prepared, standard G-banding staining technique was carried 
out and the Cytovision imaging system was used to analysis the staining results. 
 
2.2.2. Chromosome segregation analysis 
 
Genomic DNA was extracted from venous blood samples of the 
investigated individuals. Chromosome 15 segregation analysis with intragenic and 
extragenic microsatellite markers of the fibrillin gene was performed in all family 
members using amplified fragment length polymorphism analysis on an 
ALFexpress instrument (Judge et al., 2001). To determine the molecular 
background and the recurrence risk, primers for the following microsatellite 
markers were used in the analysis: D15S119, D15S1028 and MTS-1, -2, -3, -4. 
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2.2.3. Mutation screening 
 
2.2.3.1. Mutation screening in nemaline myopathy type 2 
 
In view of the morphological findings a search was initiated in 
collaboration with the commercial diagnostic company, Centogene GmbH 
(Rostock, Germany) to find the molecular genetic etiology of nemaline myopathy 
in the affected child. Tests for ACTA1 and TPM3 were negative. Eventually testing 
the NEB gene revealed two previously unreported heterozygous mutations: a 
deletion (c.24527_24528delCT p.P8176fsX8179; Figure 2a) in exon 174 and a 
duplication (c.24250_24253dupGTCA p.T8085fsX8100; Figure 2b) in exon 171. 
These mutations result in a frameshift and a premature termination codon, 
respectively, presumably leading to truncated nebulin protein. Further testing of 
the parents and their unaffected children was carried out by me in the molecular 
biology laboratory of the Department of Medical Genetics Institute (Szeged).  
Peripheral blood samples were taken from all investigated individuals. 
Genomic DNA was isolated using a BioRobot EZ1 DSP Workstation (QIAGEN; 
Hilden, Germany). The exon 171 and 174 of the NEB gene and the flanking 
introns were amplified by PCR reaction using specific primers (Table 4.).  
 
Primer Sequence 
NEB gene exon 171 forward primer TCT GGC TCC TTG GAT GAC TG 
NEB gene exon 171 reverse primer TGG GAA TGG TGT TAG GCT AGA 
NEB gene exon 174 forward primer TGG TTT GGG GCC CTA AAG AT 
NEB gene exon 174 reverse primer GGA CAG GGT TAG GAG CAG G 
 
Table 4. Primers used to amplify specific regions of the NEB gene.  
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The efficacy of the PCR reaction was checked by gel electrophoresis. PCR 
products were sequenced using ABI Prism 7000 Sequence Detection System (Life 
Technologies Magyarország Kft; Budapest). 
 
 2.2.3.2. Mutation screening in hereditary hyperekplexia type 1 
 
Primer Sequence 
GLRA1 gene exon 1 forward primer CAA TAG CGC TTT CTG GTT TTG 
GLRA1 gene exon 1 reverse primer ACC ACG GAC AGA GGT AGC C 
GLRA1 gene exon 2 forward primer TCA CAG CAT GAG AAA GAG CC 
GLRA1 gene exon 2 reverse primer CAT TAC CAT GCT GCT TGC TG 
GLRA1 gene exon 3 forward primer CCT ACC CTG TGG GTT CTT CC 
GLRA1 gene exon 3 reverse primer TGC AGA GGA TAA ATA TTT CAT GGA G 
GLRA1 gene exon 4 forward primer CAA AAG TTG ATG TCC TTG GG 
GLRA1 gene exon 4 reverse primer GCC TGT TCA CCT CTG TTT GG 
GLRA1 gene exon 5 forward primer ACA GCC TCC CTG ATG TGC 
GLRA1 gene exon 5 reverse primer AGC TGT GTG GGA ATT TCT GC 
GLRA1 gene exon 6 forward primer TGC TTC AAA CAA GTG CTT CTG 
GLRA1 gene exon 6 reverse primer ATG ACC TCT GGT CCT GGT TG 
GLRA1 gene exon 7 forward primer TCT AAT CCT AAA GCC TTT TGT CC 
GLRA1 gene exon 7 reverse primer AGG CAG AGC AAG GAA GTA GG 
GLRA1 gene exon 8 forward primer TGT GGG GAA TTA CCG AAG AG 
GLRA1 gene exon 8 reverse primer TTG AGA AGG ATG GAC CAT TG 
GLRA1 gene exon 9 forward primer AGT GCC TTG CAG GGA GG 
GLRA1 gene exon 9 reverse primer ATT CCT GTG CTA TTC CCA CG 
 
Table 5. Primers used to amplify specific regions of the GLRA1 gene.  
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Peripheral blood samples were taken from all investigated individuals. 
Genomic DNA was isolated using a BioRobot EZ1 DSP Workstation (QIAGEN; 
Hilden, Germany). The coding regions and the flanking introns of the GLRA1 
gene were amplified by PCR reaction using specific primers (Table 5.). The 
efficacy of the PCR reaction was checked by gel electrophoresis. PCR products 
were sequenced using ABI Prism 7000 Sequence Detection System (Life 
Technologies Magyarország Kft; Budapest). 
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3. Results 
 
3.1. Results in Angelman syndrome 
 
3.1.1. Pre-test counselling in Angelman syndrome 
 
A 16-month-old Hungarian child with clinical symptoms of a suspected 
genetic disorder and his family were sent for genetic counselling and cytogenetic 
and genetic investigations to our institute by the child neurologist. During pre-test 
genetic counselling the parents were informed about the purpose of the cytogenetic 
and genetic studies.  
The aim of the cytogenetic investigation was to detect any numerical 
and/or structural abnormalities in the chromosome set of the cells, which can be a 
putative causative alteration in the background of a genetic syndrome. The parents 
were also informed about the putative causative alteration of the chromosomes 15 
in the background of Prader-Willi/Angelman syndrome. The significance of the 
investigations was the identification of the genetic cause, which would strongly 
support the clinical diagnosis and would help to estimate the course and the 
prognosis of the disease.  
 The parents were also informed about the method of the cytogenetic 
investigation and about the time it requires.  
Cytogenetic studies were the first choice to elucidate the causative 
abnormality in the patient with clinical symptoms of delayed speech development 
and dysmorphic features. After the detection of the rearrangement of 
chromosomes 15 in the patient, further genetic investigations were carried out to 
analyze the paternal or maternal origin of the alteration.  
Besides these details, the parents were also informed about the legal 
regulations on the cytogenetic and genetic investigations and they gave their 
written informed consent before the investigations were started.  
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3.1.2. Genetic investigation revealed paternal isochromosome 15q UPD 
 
Cytogenetic analysis demonstrated a 45,XY,der(15;15)(q10;q10) karyotype 
(Figure 7.) in all analyzed cells from the 16-month-old patient (III/1, Figure 3.). 
All metaphase cells displayed 45 chromosomes, suggesting a balanced 
homologous rearrangement of the long arms of chromosomes 15. The parent’s 
karyotype was found to be normal, indicating a de novo chromosome 
rearrangement in the patient.  
 
 
 
Figure 7. The karyotype of the patient with clinical symptoms of Angelman 
syndrome. 
 
 
Analysis of polymorphic STR markers of the fibrillin-1 gene, which is 
located in 15q21.1, revealed that both long arms of the aberrant chromosome 15 
were inherited from the father (Figure 8.), allowing a diagnosis of Angelman 
syndrome caused by paternal UPD. The patient was homozygous at all loci for 
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which his father was heterozygous, indicating that the rearrangement resulted from 
a isochromosome 15q. 
 
 
Figure 8. Genetic analysis of the affected family using polymorphic STR markers 
MTS2, D15S119 and D15S1028 for the fibrillin-1 gene.  
 
3.1.3. Post-test counselling in Angelman syndrome 
 
During the post-test genetic counselling, the parents were informed about 
the balanced structural chromosomal rearrangement 45,XY,der(15;15)(q10;q10) 
identified at the affected child. The performed investigations also revealed that the 
parents are not carriers of the balanced translocation of chromosomes 15, it 
emerged de novo in the infant. In order to prove the causative relationship between 
the carrier status of the balanced translocation and the clinical symptoms of the 
patient further genetic study was performed to identify the parental origin of 
chromosome 15. It was explained in details for the parents that the paternal origin 
of chromosome 15 would suggest Angelman syndrome, while its maternal origin 
would indicate Prader-Willi syndrome and its biparental origin would not likely to 
cause any clinical symptoms. The performed segregation analysis of chromosome 
15 suggested paternal origin and thus Angelman syndrome.  The cytogenetic and 
genetic finding correlated well with the clinical symptoms of the affected child 
such as the detected minor anomalies, the developmental delay in speech and the 
sleeping abnormality. According to the literature, Angelman syndrome caused by 
paternal UPD is less severe in its course and prognosis compared to Angelman 
syndrome with other causative abnormalities. The importance of the appropriate 
 27 
 
diet was emphasized for the parents, since this form is associated with increased 
risk of obesity. Regarding family planning, the parents were informed about the 
very low risk - new mutation rate equivalent - of recurrence, since the identified 
abnormality emerged de novo in the affected child.  
 
3.2. Results in nemaline myopathy  
 
3.2.1. Pre-test counselling in nemaline myopathy 
 
The 4-year-old Hungarian child with nemaline myopathy type 2 and his 
family were sent for genetic counselling and the cytogenetic and genetic 
investigations to our institute by the child neurologist. The affected child was 
previously investigated in abroad (Centogene GmbH Rostock, Germany) and two 
compound heterozygous mutations were identified in the NEB gene 
(c.24527_24528delCT p.P8176fsX8179 and c.24250_24253dupGTCA 
p.T8085fsX8100), which were considered as causative abnormalities for nemaline 
myopathy type 2. He was referred with his family for genetic counselling and 
further genetic investigations, since his mother was 9-week-old pregnant and was 
expecting her fifth baby. Previously the parents and the clinically unaffected 
brother and sisters of the patient were not investigated.  
During pre-test genetic counselling the parents were informed about the 
purposes of the genetic studies, which were the followings: To verify the presence 
of the two heterozygous mutations of the NEB gene in the affected child, to 
identify the possible carrier status of the parents and the unaffected siblings and to 
provide the option of the prenatal diagnostic testing for the pregnant mother. The 
parents were also informed about the method of the genetic investigation and 
about the time it requires.  
Besides these details, the parents were also informed about the legal 
regulations on the genetic investigations and they gave their written informed 
consent before the investigations were started.  
 
 28 
 
3.2.2. Genetic investigation revealed parental origin of the mutations  
 
Using direct sequencing the performed genetic investigations confirmed 
the presence of the two compound heterozygous mutations in the NEB gene in the 
affected child. One of the mutation was a heterozygous deletion 
(c.24527_24528delCT p.P8176fsX8179) in exon 174, while the other was a 
heterozygous duplication (c.24250_24253dupGTCA p.T8085fsX8100) in exon 
171 (Figure 9.). These mutations result in a frameshift and a premature termination 
codon, respectively, presumably leading to truncated nebulin protein.  
 
    
 
Figure 9. Identification of two heterozygous mutations - one deletion and one 
duplication -  in the NEB gene. 
Further testing of the parents revealed that the father carries the deletion 
and the mother has the heterozygous duplication (Figure 10.). One of the two 
sisters of the patient carries wild type alleles, while another sister and the brother 
are heterozygous for the duplication (Figure 10.). Thus, the clinically unaffected 
family members carry either wild type alleles or only one of the mutant alleles; 
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either the duplication or the deletion. The patient however is a compound 
heterozygous carrier of both mutations. 
 
    
 
Figure 10. Genetic screening of the affected family. The patient (II/4) and his 
clinically unaffected father (I/1) carry the deletion in heterozygous form, while the 
other unaffected family members (I/2, II/1, II/2, II/3) carry the wild type allele. 
The patient (II/4) and his clinically unaffected mother (I/2), brother (II/2) and 
sister (II/3) carry the duplication in heterozygous form, while the other unaffected 
family members (I/1, II/1) carry the wild type allele. These results suggest that the 
deletion is of paternal origin and the duplication is of maternal origin.  
 
3.2.3. Post-test counselling in nemaline myopathy  
 
During the post-test genetic counselling, the parents were informed about 
their carrier status. In details, the performed investigations proved the presence of 
both previously identified mutation in the affected child and revealed that the 
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deletion has paternal and the duplication has maternal origin. The performed 
investigations also revealed that two of the clinically unaffected siblings are also 
carrier of the maternal duplication and none of the clinically unaffected siblings 
are carrier of the paternal deletion.  
These results had high impact on family planning, since they suggested 
autosomal recessive inheritance of the disease and proved that there is a 25% 
chance of expecting an affected child from the 5
th
 pregnancy of the mother.  
Based on the above findings, chorion villus sampling, fetal DNA isolation 
and fetal genetic testing were offered for the pregnant mother to detect the two 
investigated mutations of the NEB gene and to ensure the delivery of a healthy 
newborn. However, after detailed discussion with the genetic counsellor and with 
the family members and other relatives, the mother did not chose to undergo 
prenatal genetic testing, but referring to social causes she requested the termination 
of pregnancy before the 12
th
 gestational week.   
 
3.3. Results in hereditary hyperekplexia 
 
3.3.1. Pre-test counselling in hereditary hyperekplexia  
 
A 27-year-old pregnant woman on the 10
th
 gestational week arrived for 
genetic counselling to assess recurrence risk of hereditary hyperekplexia and 
discuss prenatal genetic testing possibilities. She reported on her second child who 
suffers from hereditary hyperekplexia. Genetic testing was not performed 
previously.  
During pre-test genetic counselling the purposes of the genetic studies were 
set and were the followings: To identify the causative abnormality of hereditary 
hyperekplexia in the affected child, to determine inheritance and recurrence risk 
with the identification of the possible paternal origin of the alteration and to 
provide the option of the prenatal diagnostic testing for the pregnant mother. The 
mother was also informed about the method of the genetic investigation and about 
the time it requires.  
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Besides these details, the mother was also informed about the legal 
regulations on the genetic investigations. After discussing this topic with the whole 
family, both parents gave their written informed consents and the genetic 
investigations were initiated.  
 
3.3.2. Genetic investigation revealed heterozygous missense mutation 
 
The most common form of hereditary hyperekplexia develops as the 
consequence of mutations in the GLRA1 gene. Therefore, direct sequencing of the 
coding regions and the flanking introns of the GLRA1 gene was performed and 
revealed a novel heterozygous missense mutation (c.211A/T, p.Ile71Phe) in exon 
3 (Figure 11.).  
 
Figure 11. Identification of a novel heterozygous missense mutation of the GLRA1 
gene. 
Comparison of GLRA1 protein sequences in the region of the mutation 
(p.Ile71Phe) from different species indicates that the region is highly conserved 
(Figure 12.). 
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Figure 12. Conservation of the region of the mutation throughout the evolution. 
 
Genetic screening of the affected family revealed that the clinically 
unaffected parents (I/1 and I/2) and the unaffected sister (II/1) did not carry the 
mutation, suggesting that the identified novel sequence alteration is a de novo 
mutation in the patient. 
 
3.3.3. Post-test counselling in hereditary hyperekplexia  
 
During the post-test genetic counseling, the parents were informed about 
the identified novel heterozygous de novo missense mutation in the affected child. 
It was emphasized that the parents did not carry the identified mutation therefore 
the risk of disease recurrence is very low and correlate with the risk of new 
mutation appearance rate. Based on the results prenatal diagnostic testing for 
hereditary hyperekplexia is not required. The results of the performed genetic 
testing suggest autosomal dominant inheritance, which will be an important issue 
when the affected child will grow up and will decide family planning.  
 
 
 
 33 
 
4. Discussion 
 
4.1. Angelman syndrome caused by paternal isochromosome 15q UPD  
 
In this study the case of a 16-month-old Hungarian boy affected by delayed 
psychomotor development and dysmorphic features is reported. Cytological and 
molecular genetic investigation revealed UPD suggesting a Robertsonian-like 
translocation 45,XY,der(15;15)(q10;q10). A similar balanced 15;15 translocation 
resulting from paternal UPD in a child with Angelman syndrome was reported by 
Freeman et al. (1993). Results from polymorphic marker analysis for the fibrillin-1 
gene, located in 15q21.1, indicated that both arms of the aberrant chromosome 15 
were inherited from the father, allowing the diagnosis of Angelman syndrome 
caused by paternal UPD. DNA polymorphic markers demonstrated that the patient 
was homozygous at all loci for which the father was heterozygous, suggesting that 
the structural rearrangement was an isochromosome 15q and not a Robertsonian 
translocation. 
The severity of Angelman syndrome varies significantly. The mildest 
symptoms have been reported for mutations of the UBE3A gene, whereas the most 
severe symptoms are reported for large deletions on chromosome 15 (Bottani et 
al., 1994; Tonk et al., 1996; Smith et al., 1997; Prasad et al., 1997; Moncla et al., 
1999). Previous studies suggested that patients with Angelman syndrome caused 
by UPD may remain undiagnosed because of their milder or less typical 
phenotype, leading to an overall under-diagnosis of the disease (Lossie et al., 
2001; Varela et al., 2004).
 
In the investigated patient, we observed dysmorphic 
features, developmental delay, speech impairment and sleep disturbances, 
excessive mouthing behavior, short attention span, hand flapping, fascinating with 
water, and characteristic EEG and MRI results. The clinical features of our patient 
are similar to previously published results (Table 6.). The symptoms of the patient 
are relatively mild, which correlates well with the previous observations that 
Angelman syndrome patients with UPD usually have less severe clinical 
symptoms (Table 6.) 
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The analyzed parameters                     
at diagnosis 
Values for the 
Hungarian patient with 
Angelman syndrome 
Values for 13 patients 
with Angelman 
syndrome  
Age (months) at diagnosis   
0-24 1 0 
25-36 - 5 
37-60 - 8 
Gender M 8M/5F 
Short attention span + 12/13 (92%) 
History of sleep difficulties + 12/13 (92%) 
Normal tone at evaluation + 12/13 (92%) 
Mouthing behavior + 11/13 (85%) 
Hand flapping + 11/13 (85%) 
Drooling + 10/13 (77%) 
Feeding difficulties in infancy - 10/13 (77%) 
Ataxic or broad based gait - 8/11 (73%) 
Gastro-esophageal reflux - 9/13 (69%) 
Widely spaced teeth + 9/13 (69%) 
Fascination with water + 8/13 (62%) 
Easily provoked laughter + 8/13 (62%) 
Clinical seizures - 6/13 (46%) 
BMI>85% + 6/13 (46%) 
Unusually light hair or skin color  - 3/13 (23%) 
Prognathism - 3/13 (23%) 
Mid-face hypoplasia - 2/13 (15%) 
Table 6. The clinical features of the Hungarian patient compared to the 13 patients 
with UPD/imprinting defects summarized by Tan et al. (2011). 
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The patient was diagnosed with Angelman syndrome at the age of 16 
months, earlier than in previous reports of UPD, allowing the parents to be given a 
correct prognosis and an explanation of delayed neurological developmental as 
well as the possibility of early interventional therapy . In addition, the 
parents were counselled that the child is at risk for obesity and its associated 
complications, which could be managed with lifestyle adjustments. As the 
aberration was the result of a de novo occurrence, the parents were not counselled 
on the risk of recurrence for further pregnancies.  
 
4.2. Nemaline myopathy type 2 caused by compound heterozygous 
mutations with parental origin 
 
Nemaline myopathies are a clinically and molecularly heterogeneous group 
of congenital myopathies (Wallgren-Pettersson et al., 2011; Nance et al., 2012). 
The combination of characteristic clinical and histopathologic features are 
diagnostic for the disorder in most cases (North et al., 2011).  The presence of red 
inclusions detected with Gomori trichrome staining and of rod-shaped particles in 
toluidine blue stained tissue from the patient strongly suggest nemaline myopathy 
(Wallgren-Pettersson et al., 2011; Nance et al., 2012). Ultrastructural studies 
reveal nemaline bodies as electron-dense, rod-shaped structures appearing as 
thickened Z-disks (Wallgren-Pettersson et al., 2011; Nance et al., 2012). Muscle 
imaging by MR can be helpful to visualize the pattern of selective muscle 
involvement and guide in localizing the site of the biopsy (Fischer et al., 2006; 
Mercuri et al., 2007). 
The work up of a case with nemaline myopathy is further complicated by 
its heterogeneous genetic background: eight known causative genes have been 
linked to this condition and both autosomal dominant and recessive inheritance has 
been observed (Wallgren-Pettersson et al., 1999 and 2011). Six of these genes 
encode proteins associated with sarcomeric thin filaments (Wallgren-Pettersson et 
al., 1999 and 2011). Recessive mutations in the NEB gene, located on 
chromosome 2q22-23 are the most commonly recognized cause of the disease 
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(Labeit et al., 2011). This gene has 182 exons and missense, nonsense and 
frameshift mutations have been reported (Wallgren-Pettersson et al., 2002). 
Hotspots have not been found and many patients proved to be compound 
heterozygotes for two mutations within the gene (Wallgren-Pettersson et al., 
2002). The nebulin protein has a wide range of functions, including thin filament 
length specification and regulation of muscle contraction (Labeit et al., 2011).   
The clinical, histological and molecular genetic findings in our patient are 
consistent with the typical congenital form of nemaline myopathy type 2, caused 
by mutations in the NEB gene (Wallgren-Pettersson et al., 2002). Compound 
heterozygosity for two novel mutations was found. A 2-base deletion 
(c.24527_24528delCT, p.P8176fsX8179) was inherited from the father and a 4-
base duplication (c.24250_24253dupGTCA, p.T8085fsX8100) from the mother. 
These novel mutations led to a translational frameshift and a premature 
termination codon in the respective translated sequences and thus, presumably, to 
truncated nebulin protein.  
 Nemaline myopathy is a debilitating condition and further research is 
warranted in order to explore the details of the molecular pathology of this 
disorder. These efforts are complicated by the heterogenic molecular background 
of the disease and the fact that certain genes encode very large proteins, like 
nebulin. Molecular diagnosis however becomes available for more and more 
patients supporting preimplantation or prenatal diagnosis for subsequent 
pregnancies. This case report extends the genetic profile of nemaline myopathy 
with two previously unreported mutations in the NEB gene. 
 
4.3. Hereditary hyperekplexia caused by de novo missense mutation 
 
In this study, a Hungarian family with one affected patient with hereditary 
hyperekplexia, a potentially fatal neurological disorder characterized by 
pronounced startle responses, was investigated. Abnormal movements, stiffness 
and convulsions were first noted in the patient at day 4 post-term, which correlates 
well with the early-onset of the disease. The initial severe symptoms of the patient 
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were attenuated by carbamazepine therapy and physiotherapy and subsequently 
diminished with age.  
Hereditary hyperekplexia has been linked to genetic alterations in genes 
involved in an inhibitory neurotransmitter, glycine neurotransmission (Harvey et 
al., 2008; James et al., 2012). GLRA1 mutations account for approximately 30% of 
all cases with hereditary hyperekplexia (Rees et al., 1994). Both compound 
heterozygous patients and homozygous mutation carriers have been described in 
the literature for recessive forms of the disease (Humeny et al., 2002). A 
heterozygous missense mutation (c.211A/T, p.Ile71Phe) was detected in the 
patient in exon 3 of the GLRA1 gene, establishing the diagnosis of hereditary 
hyperekplexia type 1 and suggesting that the mutation is an autosomal dominant 
form of the disease. As the non-coding regions of the GLRA1 gene were not 
examined, we cannot exclude the possibility of second mutation that represents a 
recessive form in our patient. 
The GLRA1 gene encodes a neurotransmitter-gated ion channel 
transmembrane protein with three transmembrane segments (Lynch et al., 2004; 
Becker et al., 2006).
 
Binding of glycine to its receptor increases the chloride 
conductance, produces hyperpolarization and, thus, the inhibition of neuronal 
firing (Lynch et al., 2004; Becker et al., 2006).
 
Previous studies have attributed 
dominant forms of hereditary hyperekplexia type 1 to mutations within the pore-
lining transmembrane segment (No.: 2) and adjacent regions, recessive forms to 
mutations within the other transmembrane segments (No.: 1 and 3), and the null 
allele of the GLRA1 gene to the deletion of exons 1–7 (Lynch et al., 2004; Becker 
et al., 2006).  
 
 
 
Figure 13. Location of the novel missense mutation on the GLRA1 protein. 
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The novel heterozygous missense mutation (p.Ile71Phe) reported here is 
located close to the NH2-terminal of the GLRA1 protein outside the 
transmembrane segments (Figure 13), in a highly conserved region (Figure 12). 
The mutation is located in a region that is not predicted or known to be a 
functional domain of the GLRA1 protein. Other missense mutations have been 
detected in this region in patients with hereditary hyperekplexia type 1 
(p.Trp68Cys and p.Arg72His; Harvey et al., 2008), and in spasmodic mouse 
(p.Ala52Ser; Saul et al., 1994). The functional analysis performed on the 
spasmodic mouse model suggested that the p.Ala52Ser missense mutation results 
in reduced glycine sensitivity (Saul et al., 1994). Based on these previous studies, 
we hypothesize that the reported novel missense mutation detected in our 
Hungarian patient might lead to reduced glycine sensitivity as well.  
It is also interesting to note, that previously reported missense mutations in 
this region (human p.Trp68Cys and p.Arg72His and murine p.Ala52Ser) are all 
associated with the recessive form of hereditary hyperekplexia type 1, indicating 
the possibility that other undetected mutations might contribute to the clinical 
symptoms of our Hungarian patient. 
Having identified the putative causative mutation in the affected patient, 
clinically unaffected family members were also screened and shown to carry only 
wildtype sequence of the GLRA1 gene. Our results suggest that this novel 
missense sequence change (c.211A/T, p.Ile71Phe) identified in the affected patient 
is a de novo mutation. Our results correlate well with the data of the literature 
indicating that approximately 70% of the disease-causing GLRA1 mutations rise de 
novo (Kang et al., 2008).  
The consequences of the hereditary hyperekplexia type 1 can be severe, 
warranting further efforts to elucidate the nature of the disease despite the 
complications implicit with the heterogenic genetic background. With the 
identification of the underlying genetic abnormalities, prenatal screening is 
available for affected families and allows informed family planning. In the future, 
knowledge of the genetic causes of this life-threatening disease may also 
contribute to the development of novel therapeutic alternatives. 
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4.4. Difficulties of genetic counselling in neurogenetic disorders 
 
Genetic counselling is primarily dependent upon precise diagnosis and 
upon accurate pedigree. The genetic counsellor always need to be careful with the 
diagnosis even if there is a clinical suspicion of certain diseases, the counsellor has 
to re-assess the symptoms of the affected patients, consider the appearance of the 
disease throughout the generations and determine the possible manners of 
inheritance.  
This accuracy of the counsellor is shown in the presented first case with 
Angelman syndrome, since the correct genetic diagnosis was established at the age 
of 16 months. To my knowledge, this is earliest diagnosed Angelman syndrome 
compared to previous reports of UPD (Table 6.), allowing the parents to be given a 
correct prognosis and an explanation of delayed neurological developmental as 
well as the possibility of early interventional therapy. In addition, the parents were 
counseled that the child is at risk for obesity and its associated complications, 
which could be managed with lifestyle adjustments. As the aberration was the 
result of a de novo occurrence, the parents were not counseled on the risk of 
recurrence for further pregnancies. 
Even if the diagnosis can suggest a group of monogenic neurogenetic 
diseases, which occurred in the case of nemaline myopathy establishing the 
accurate genetic diagnosis is still difficult. Since mutations in several genes can 
lead to the same phenotype such as the mutations of the following genes TPM3, 
NEB, ACTA1, TPM2 ,TNNT, CFL, KBTBD13, and KLHL40 can lead to the 
development of nemaline myopathy. In this case, after screening several genes, the 
causative compound heterozygous mutations were finally found in the NEB gene 
suggesting nemaline myopathy type 2. After the causative mutations were 
identified, investigation of the whole family helped to assess carrier statuses and 
the recurrence risk of the disease.  
Sometimes the identification of the putative causative mutation and 
establishing the correct genetic diagnosis are not enough for determining the mode 
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of inheritance and the recurrence risk of the diasease. This was the case with the 
Hungarian family having a child affected by hereditary hyperekplexia. With the 
identification of the novel missense heterozygous mutation of the GLRA1 gene, the 
established genetic diagnosis was hereditary hyperekplexia type 1. However, this 
type of the disease can have autosomal dominant or recessive inheritance as well. 
In case of a homozygous mutation the recessive inheritance is clear. In case of a 
heterozygous mutation the dominant inheritance can only be supposed, since there 
is a chance of an unidentified second mutation in the uninvestigated, non-coding 
regions of the GLRA1 gene.    
The development of new techniques for antenatal and prenatal diagnosis of 
chromosomal anomalies, monogenic or multifactorial disorders and an increased 
ability to recognize carriers of recessive genes greatly improve the quality of 
genetic diagnosis. The Human Genome Project also helped the discoveries of 
candidate genes and novel gene variations in the background of monogenic 
diseases such as neurogenic disorders. There is still a strong need of further 
developments, since several neurogenic disorders have no causative therapy. 
Hopefully in the future genetic counselling will not only help family planning, but 
also the initiation of personalized therapy.  
Another important aspect of genetic counselling is empathy of the 
counsellor. In counselling, simple statements of risk are rarely sufficient. Clinical 
acumen is required to perceive the unspoken fears and feelings of guilt, which are 
usually associated with inherited disease. Sometimes it is really difficult to 
eliminate unwanted and un-appropriate feelings of the parents. In the family 
affected by nemaline myopathy type 2, the mother was pregnant at the time of the 
genetic counselling and investigations. Even though, the performed investigations 
elucidated the carrier statuses of the parents, accurately determined the recurrence 
risk (25%) and provide the possibility of prenatal screening, the family decided to 
terminate the pregnancy and not to undergo chorionic villus sampling and prenatal 
screening. Behind this decision, there are several rational reason and spoken and 
unspoken feelings. As a genetic counsellor, I can help the individual or the family 
with accurate and detailed informations about the disease, prognosis, outcomes, 
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therapeutic modalities and family planning, but all the counsellors must accept that 
the final decision is made by the patient or the family.   
 
4.5. The future prospect of genetic investigations in neurogenetic 
disorders 
 
Although multifactorial diseases are more common than monogenic 
disorders, studies of the latter ones provide an invaluable opportunity to learn 
about underlying molecular mechanisms, thereby contributing a great deal to our 
understanding of all forms of genetic disease (Antonarakis & Beckmann, 2006). 
Before the human genome was sequenced, researchers relied on labor-
intensive, slow-going techniques for mapping and isolating disease-associated 
genes. For instance, although efforts to isolate the gene associated with 
Huntington's disease began in the late 1970s, the gene was not identified until 
1993. The Human Genom Project has mapped polymorphisms along the length of 
every human chromosome and has made this information freely available to 
scientists worldwide (www.hapmap.org). These polymorphic markers can be used 
to map disease-associated genes. 
In this study, polymorphic markers were used to perform segregational 
analysis of chromosome 15 in a family affected by Angelman syndrome. The 
performed genetic investigations demonstrated that the paternal origin of 
chromosome 15 in the affected child and confirmed the clinical suspect of 
Angelman syndrome. 
Due to the accelerated discoveries made in the last two decades, there are a 
wide range and huge amount of genetic and genomic findings available from 
previous studies conducted worldwide recently. In order to use these discoveries 
efficiently and make them available for the researchers worldwide, bioinformatics 
has also showed a great improvement.  
There are several examples in everyday use of bioinformatics in the 
investigation of neurogenic disorders: In this study, the neurogenic disorders were 
searched in the database of Online Mendelian Inheritance in Man (OMIM), which 
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is a regularly updated, online database established in 1997 by Dr. Victor A. 
McKusick and is focused on inherited genetic diseases in humans 
(www.omim.org). After the genetic investigations were performed, the obtained 
sequencing data was compared to the ones in the Ensemble Genome Browser 
(www.ensemble.org) and was screened for diseases causing variations. Possible 
impacts of genetic variations were checked by using PolyPhen-2 
(http://genetics.bwh.harvard.edu/pph2/).  
These recent improvements demonstrate that the field of neurogenetics 
develops rapidly, which means that the genetic counsellor needs to be always 
update and keep up with the developments of this field. Since neurogenetics is 
now in the focus of research of several groups worldwide, hopefully the 
forthcoming future developments will not only elucidate the disease-causing 
genetic abnormalities of neurogenetic disrorders, but will provide a solid basis for 
the development of novel therapeutic modalities for the affected patients.     
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5. Summary 
 
In this study, my aim was to summarize the genetic investigations and the 
difficulties of the genetic counselling on family planning in Hungarian families 
affected by three different neurogenetic disorders such as Angelman syndrome, 
nemaline myopathy and hereditary hyperekplexia.  
Angelman syndrome is a rare neurogenetic disorder that results in 
intellectual and developmental disturbances, seizures, jerky movements and 
frequent smiling. Angelman syndrome is caused by two genetic disturbances: 
genes on the maternally inherited chromosome 15 are deleted or inactivated or two 
paternal copies of the corresponding genes are inherited. The results of this study 
allowed the earliest reported diagnosis of Angelman syndrome in a 16-month-old 
child with clinical symptoms. The patient was referred with minor facial 
anomalies, neurodevelopmental delay and speech impairment. Cytogenetic results 
suggested a de novo Robertsonian-like translocation involving both q arms of 
chromosome 15: 45,XY,der(15;15)(q10;q10). Molecular genetic studies with 
polymorphic markers of the fibrillin-1 gene, located in the 15q21.1, revealed that 
both arms of the translocated chromosome were derived from a single paternal 
chromosome 15 (isodisomy) and led to the diagnosis of Angelman syndrome 
caused by UPD. Angelman syndrome resulting from UPD caused by de novo 
balanced translocation t(15q;15q) of a single paternal chromosome has been 
reported by other groups. The detection of this rare UPD cause of Angelman 
syndrome contributes to the deeper understanding of the phenotype-genotype 
correlation in Angelman syndrome for non-deletion subclasses. 
Nemaline myopathy is a type of the heterogeneous group of congenital 
myopathies. Generalized hypotonia, weakness and delayed motor development are 
the main clinical features of the typical congenital form. Histopathology shows 
characteristic nemaline rods in the muscle biopsy. Mutations in at least seven 
genes proved to be responsible for this muscle disease. Here I have investigated a 
Hungarian family with a child affected by nemaline myopathy type 2 caused by 
compound heterozygosity for two novel mutations, a deletion and a duplication in 
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the NEB gene. The deletion was inherited from the father and the duplication from 
the mother. Since nemaline myopathy is a debilitating condition, further research 
is warranted in order to explore the details of the molecular pathology of this 
disorder. These efforts are complicated by the heterogenic molecular background 
of the disease. Molecular diagnosis however becomes available for more and more 
patients supporting preimplantation or prenatal diagnosis for subsequent 
pregnancies. Here I report extends the genetic profile of nemaline myopathy with 
two previously unreported mutations in the NEB gene. 
Hereditary hyperekplexia is a neurological disorder characterized by 
excessive startle responses with violent jerking to noise or touch, stiffening of the 
trunk and limbs, clenching fists and attacks of a high-frequency trembling. 
Hereditary hyperekplexia has a heterogeneous genetic background with several 
identified causative genes and demonstrates both dominant and recessive 
inheritance. Mutations in the GLRA1 gene occur in about 30% of the cases. In this 
study, I report a Hungarian pedigree with one affected boy whose abnormal 
movements, muscle stiffness and convulsions were first noted when he was 4 days 
old. Neurological and electrophysiological investigation suggested the clinical 
diagnosis of hereditary hyperekplexia. Direct sequencing of the coding regions and 
the flanking introns of the GLRA1 gene revealed a novel heterozygous missense 
mutation (c.211A/T, p.Ile71Phe). Genetic screening of the patient's family 
revealed that the clinically unaffected parents and sister do not carry the mutation 
suggesting that the identified sequence change is a de novo mutation. Since 
hereditary hyperekplexia can have severe consequences, including sudden infant 
death due to laryngospasm and cardiorespiratory failure, identification of the 
causative genetic alteration(s) of the disease is high priority. Such knowledge is 
necessary for prenatal diagnosis, which would allow informed family planning and 
greater parental sensitivity to hereditary hyperekplexia-associated risks. 
My investigations have great importance for the affected families since 
they help family planning. Hopefully, these findings might also provide the basis 
of future studies for the development of novel therapeutic modalities in 
neurogenetic disorders. 
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9. Abbreviations 
 
ACTA1: skeletal muscle α-actin gene 
AD: autosomal dominant inheritance 
AR: autosomal recessive inheritance 
ARHGEF9: postsynaptic glycine enhancer collybistin gene  
CFL2: cofilin-2 gene 
GLRA1: glycine receptor alpha 1 subunit gene  
GLRB: glycine receptor beta subunit gene 
GPHN: glycine receptor locator gephyrin gene 
IBD: identity by descent 
KBTBD13: kelch-repeat and BTB (POZ) domain containing 13   
KLHL40: kelch-like family member 40  
LOD: logarithm of odds 
NEB: nebulin gene 
OMIM: Online Mendelian Inheritance in Man 
SLC6A5: glycine transporter solute carrier family 6 member 5 gene 
STR: short tandem repeat  
TPM2: β-tropomyosin gene 
TPM3: α-tropomyosin gene 
TNNT1: muscle troponin T1 gene 
UBE3A: ubiquitin protein ligase E3A  
UPD: uniparental disomy 
XR: X-linked recessive inheritance 
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Early detection of Angelman syndrome resulting
from de novo paternal isodisomic 15q UPD and
review of comparable cases
Emese Horváth1*, Zsuzsanna Horváth1, Dóra Isaszegi1, Gyurgyinka Gergev2, Nikoletta Nagy1,3, János Szabó1,
László Sztriha2, Márta Széll1,3 and Emőke Endreffy2
Abstract
Background: Angelman syndrome is a rare neurogenetic disorder that results in intellectual and developmental
disturbances, seizures, jerky movements and frequent smiling. Angelman syndrome is caused by two genetic
disturbances: either genes on the maternally inherited chromosome 15 are deleted or inactivated or two paternal
copies of the corresponding genes are inherited (paternal uniparental disomy). A 16-month-old child was referred
with minor facial anomalies, neurodevelopmental delay and speech impairment. The clinical symptoms suggested
angelman syndrome. The aim of our study was to elucidate the genetic background of this case.
Results: This study reports the earliest diagnosed angelman syndrome in a 16-month-old Hungarian child.
Cytogenetic results suggested a de novo Robertsonian-like translocation involving both q arms of chromosome 15:
45,XY,der(15;15)(q10;q10). Molecular genetic studies with polymorphic short tandem repeat markers of the fibrillin-1
gene, located in the 15q21.1, revealed that both arms of the translocated chromosome were derived from a single
paternal chromosome 15 (isodisomy) and led to the diagnosis of angelman syndrome caused by paternal
uniparental disomy.
Conclusions: AS resulting from paternal uniparental disomy caused by de novo balanced translocation t(15q;15q) of
a single paternal chromosome has been reported by other groups. This paper reviews 19 previously published
comparable cases of the literature. Our paper contributes to the deeper understanding of the phenotype-genotype
correlation in angelman syndrome for non-deletion subclasses and suggests that patients with uniparental disomy
have milder symptoms and higher BMI than the ones with other underlying genetic abnormalities.
Keywords: Angelman syndrome, Isodisomic 15, Uniparental disomy, Balanced translocation chromosome 15q
Background
Angelman syndrome (AS; OMIM 105830) is a rare neuro-
developmental disorder characterized by severe mental
and physical delay, limited speech, fine tremor, ataxia, ex-
cessive mouthing behavior, fascination with water, jerky
limb movements, seizures, craniofacial abnormalities and
unusually happy sociable behavior characterized by fre-
quent episodes of inappropriate smiling [1,2].
Seventy percent of AS cases investigated with molecular
genetics methods are the result of a small deletion in the
11–13 region of the maternal chromosome 15. A deletion
in the same region of the paternal chromosome 15 results
in the sister disorder Prader-Willi syndrome (PWS). Ex-
pression of the genes in the 11–13 region is regulated by
the PWS/AS imprinting center (IC), which differentially
silences the paternal copy of the ubiquitin protein
ligaseE3A (UBE3A) gene in the hippocampus and in the
cerebellum. Other genetic abnormalities resulting in AS
reported include uniparental disomy (UPD; 5%), muta-
tions of the IC (5%), mutations of the UBE3A gene (10%),
and other mechanisms (10%) [3,4].
In this paper, we report a 16-month-old Hungarian
child, who was referred to our genetic counseling unit
with delayed psychomotor and speech development and
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dysmorphic features, including wide nasal bridge, low
set ears, thick lips, wide mouth with protuberant tongue
(Figure 1). Tongue thrusts were observed. Head circum-
ference was 47 cm (25 percentile). The affected child
was born at term after an uneventful first pregnancy
with normal weight (3260 g) and head circumference
(33 cm). The Apgar scores were 9, 10 and 10 at 1, 5 and
10 minutes, respectively. No signs of decreased fetal
movement, neonatal hypotonia or feeding difficulties
were reported. The clinical phenotype of the patient
suggested AS, therefore molecular cytogenetic investi-
gations were carried out to elucidate the genetic back-
ground of the presented case.
Results
Cytogenetic analysis demonstrated a 45,XY,der(15;15)
(q10;q10) karyotype in all analyzed cells from the index
patient (III/1, Figure 2). All metaphase cells displayed 45
chromosomes, suggesting a balanced homologous re-
arrangement of the long arms of chromosomes 15. The
parent’s karyotype was found to be normal, indicating a
de novo chromosome rearrangement in the patient.
Analysis of polymorphic short tandem repeat (STR)
markers of the fibrillin-1 gene, which is located in
15q21.1, revealed that both long arms of the aberrant
chromosome 15 were inherited from the father (Figure 3),
allowing a diagnosis of AS caused by paternal UPD. The
patient was homozygous at all loci for which his father
was heterozygous, indicating that the rearrangement
resulted from an isodisomic 15q.
Discussion
Cytological and molecular genetic investigation revealed
UPD suggesting a Robertsonian-like translocation 45,XY,
der(15;15)(q10;q10), a rearrangement of the acrocentric
chromosomes. Robertsonian translocations mostly form
de novo due to intrinsic properties of the acrocentric
chromosomes, which are likely to be the results of the
high homology between the short arm DNA sequences
of them [5]. A similar balanced 15;15 translocation
resulting from paternal UPD in AS were reported by
Freeman et al. (1993) [6], by Tonk et al. (1996) [7], by
Ramsden et al. (1996) [8], by Guitart et al. (1997) [9],
by Fridman et al. (1998) [10] and by Robinson et al.
(2000) [11].
Results from polymorphic STR marker analysis for the
fibrillin-1 gene, located in 15q21.1, indicated that both
arms of the aberrant chromosome 15 were inherited
from the father, allowing a diagnosis of AS caused by pa-
ternal UPD. DNA polymorphic markers demonstrated
that the patient was homozygous at all loci for which the
father was heterozygous, suggesting that the structural re-
arrangement was an isodisomic 15q and not a Robertsonian
translocation. Similar cases of AS resulting from isodisomic
15q associated UPD have already been demonstrated by
Freeman et al. (1993) [6] and by Robinson et al. (2000)
[11], however, the majority of the previously reported pater-
nal UPD associated AS cases were heterodisomic [7-10].
The severity of AS symptoms varies significantly.
Bottani et al. (1994) were the first, who reported that
the phenotype of AS with paternal isochromosome 15 is
milder than those caused by other mechanisms [12].
This observation was confirmed by Tonk et al. (1996)
[7], Smith et al. (1997) [13], Fridman et al. (1998) [10]
and Moncla et al. (1999) [14], however Prassad et al.
(1997) [15] have not observed differences between dele-
tion and UPD, moreover Poyatos et al. (2002) described
an even more severe phenotype [3]. The mildest symp-
toms have been reported for mutations of the UBE3A
gene [2,12,14,16], whereas the most severe symptoms
are reported for large deletions on chromosome 15
[2,14,16]. Varela et al. (2004) suggested that AS patients
with UPD may remain undiagnosed because of their
milder or less typical phenotype, leading to an overall
under-diagnosis of the disease (Table 1) [17,18]. Ac-
cording to Tan et al. (2011) [4], 46% of AS children with
UPD/imprinting defect showed significantly higher body
mass index (BMI) than the ones carrying deletions.
In the investigated patient, we observed dysmorphic fea-
tures, developmental delay, speech impairment and sleep
disturbances, excessive mouthing behavior, short attention
span, hand flapping, fascinating with water, and characte-
ristic EEG and MRI results. The clinical features of our pa-
tient are similar to previously published results [4,7,9,12].
The patient's AS symptoms are relatively mild, which
correlates well with the previous observations that AS pa-
tients with UPD usually have less severe clinical symptoms
[8,10,11,13]. The BMI of our patients was > 85%, which
correlated well with the previous results of Tan et al.
Figure 1 Clinical features of a patient with Angelman
syndrome resulting from de novo paternal isochromosome 15q
UPD. The dysmorphic symptoms of the 16 month old child include
wide nasal bridge, low set ears, thick lips, wide mouth and
protruding tongue.
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Figure 2 The karyotype of the AS patient. The cytogenetic image displays 45 metaphase chromosomes with an apparently balanced
homologous rearrangement between the long arms of chromosomes 15. Cytogenetic result: 45,XY der(15;15)(q10;q10).
Figure 3 Genetic analysis of the affected family using polymorphic STR markers MMTS2, D15S119 and D15S1028 for the fibrillin-1
gene. Marker analysis of the patient (III/1), his parents (II/1, II/2), maternal aunts (II/3, II/4, II/5), maternal grandparents (I/3, I/4), and paternal
grandparents (I/1, I/2) was performed by ALFexpress gel electrophoresis. The patient is homozygous for polymorphisms occurring in the father
but not the mother, indicating that both arms of the aberrant chromosome 15 were of paternal origin.
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(2011) [4] and further confirmed that AS patients with
UPD have significantly higher BMI than AS patients with
other underlying genetic abnormalities.
The patient was diagnosed with AS at the age of 16
months, earlier than in previous reports of UPD,
allowing the parents to be given a correct prognosis and
an explanation of delayed neurological developmental
as well as the possibility of early interventional therapy.
In addition, the parents were counseled that the child is
at risk for obesity and its associated complications,
which could be managed with lifestyle adjustments. As
the aberration was the result of a de novo occurrence,
the parents were not counseled on the risk of recur-
rence for further pregnancies.
Conclusions
In this paper we report the case of a 16-month-old
Hungarian boy affected by AS due to UPD. The early
diagnosis of AS has great significance, it allows the pa-
rents to be given a correct prognosis and the possibility
of early interventional therapy. The detection of UPD
and reviewing the previous cases reported in the litera-
ture have also pivotal role, since it contributes to the
deeper understanding of the phenotype-genotype cor-
relation in AS for non-deletion subclasses. Our data
suggest that AS patients with UPD have milder symp-
toms and higher BMI than AS patients with other
underlying genetic abnormalities.
Methods
Cytogenetic analysis of the child and his parents was
carried out with standard methods using G banding with
the Cytovision imaging system. The results of the cyto-
genetic studies suggested UPD, and, therefore, further
molecular genetic studies were carried out. Genomic
DNA was extracted from venous blood of the index
patient (III/1), his parents (II/1, II/2), his grandparents
(I/1, I/2, I/3, I/4) and his maternal aunts (II/3, II/4, II/5)
[19]. Chromosome 15 segregation analysis with intra-
genic and extragenic markers for the fibrillin-1 gene was
performed for all family members using amplified frag-
ment length polymorphism analysis on an ALFexpress
instrument [20]. To determine the molecular back-
ground and the recurrence risk, primers for the follo-
wing microsatellite markers were used in the analysis:
D15S119, D15S1028 and MMTS2.
Consent
Written informed consent was obtained from the pa-
tient’s legal guardian for publication of this case report
and accompanying images. A copy of the written con-
sent is available for review by the Editor-in-Chief of this
journal.
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Table 1 The clinical features of the patient, in order of
frequency, compared to the 13 AS patients with UPD/
imprinting defects reported by Tan [4]
The analyzed
parameters at
diagnosis
Values for the
patient described in
this report
Values for the 13 AS
patients with UPD/
imprinting defects
reported by Tan [4]
Age (months) at
diagnosis
0–24 1 0
25–36 - 5
37–60 - 8
Gender M 8M/5F
Short attention
span
+ 12/13 (92%)
History of sleep
difficulties
+ 12/13 (92%)
Normal tone at
evaluation
+ 12/13 (92%)
Mouthing
behavior
+ 11/13 (85%)
Hand flapping + 11/13 (85%)
Drooling + 10/13 (77%)
Feeding
difficulties in
infancy
- 10/13 (77%)
Ataxic or broad
based gait
- 8/11 (73%)
Gastro-esophageal
reflux
- 9/13 (69%)
Widely spaced
teeth
+ 9/13 (69%)
Fascination with
water
+ 8/13 (62%)
Easily provoked
laughter
+ 8/13 (62%)
Clinical seizures - 6/13 (46%)
BMI>85% + 6/13 (46%)
Unusually light
hair or skin color
- 3/13 (23%)
Prognathism - 3/13 (23%)
Mid-face
hypoplasia
- 2/13 (15%)
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Brief Communication
Nemaline Myopathy Type 2 (NEM2):
Two Novel Mutations in the Nebulin
(NEB) Gene
Anna Gajda, MD1, Emese Horva´th, MD2, Tibor Hortoba´gyi, MD, PhD3,
Gyurgyinka Gergev, MA1,4, Hajnalka Szabo´, MD, PhD1, Katalin Farkas, BSc5,
Nikoletta Nagy, MD, PhD2,5, Ma´rta Sze´ll, MSc, PhD, DSc2,5, and
La´szlo´ Sztriha, MD, PhD, DSc1
Abstract
Nemaline myopathy is a type of the heterogeneous group of congenital myopathies. Generalized hypotonia, weakness, and
delayed motor development are the main clinical features of the typical congenital form. Histopathology shows characteristic
nemaline rods in the muscle biopsy. Mutations in at least 7 genes, including nebulin gene (NEB), proved to be responsible for this
muscle disease. We present a boy with nemaline myopathy type 2 (NEM2) caused by compound heterozygosity for 2 novel
mutations, a deletion and a duplication in the NEB gene. The deletion was inherited from the father and the duplication from the
mother. Testing all family members supports genetic counseling.
Keywords
congenital myopathy, hypotonia, nebulin
Received April 9, 2013. Received revised April 26, 2013. Accepted for publication May 28, 2013.
Congenital myopathies are a group of genetic muscle disorders
with clinical, pathologic, and molecular heterogeneity.1 Nema-
line myopathy is a pathologically well-defined subgroup of
congenital myopathies characterized by the presence of rodlike
structures in the muscle fibers.2 The disease presents a wide
range of clinical variability and severity, although generalized
hypotonia, muscle weakness, feeding difficulties, and delay of
motor milestones are almost always present.2 All molecularly
characterized forms of nemaline myopathy are autosomal, but
inheritance can be recessive or dominant, and singleton cases
could arise from de novo dominant mutations.2,3 To date, 7
genes have been linked to this condition: a-tropomyosin
(TPM3), nebulin (NEB), skeletal muscle a-actin (ACTA1), b-
tropomyosin (TPM2), muscle troponin T1 (TNNT1), cofilin-2
(CFL2) and the recently identified KBTBD13 gene, whose
function is still unknown.2-4
Disease resulting from mutations in the NEB gene is classi-
fied as nemaline myopathy type 2 (NEM2; OMIM 256030), the
most common form of nemaline myopathy.2 NEM2 is a rare
autosomal recessive condition characterized by early-onset
muscle weakness, which is most pronounced in the axial mus-
cles and proximal limb-girdles. Weakness in facial and bulbar
muscles commonly results in dysarthria.5 The course of the
disease is nonprogressive or slowly progressive and life expec-
tancy depends on the severity of respiratory muscle weakness.
Mechanical ventilation is necessary for some patients and
orthopedic complications are frequent.6 Mental development
and intelligence are typically within the normal range.6 In this
report, we present the clinical and histologic findings in a
patient suffering from NEM2 and describe compound hetero-
zygosity for 2 novel mutations in the NEB gene.
Case Report
Clinical Presentation
The patient, a boy, was born at term from a fourth uneventful
pregnancy. Birth weight was 3450 g and Apgar scores were 9
and 10 at 5 and 10 minutes, respectively. Floppiness and weak
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cry were noticed in the neonatal period. Generalized hypotonia,
weakness, and delayed acquisition of motor milestones were
observed in early childhood. He began to walk with support
at the age of 2 years. Deep tendon reflexes were reduced. There
was no fasciculation in the tongue. He suffered also from recur-
rent respiratory tract infections. The serum creatine kinase
activity was normal. The optic fundus and brain magnetic reso-
nance imaging (MRI) were also normal. Tandem mass spectro-
metry and urine gas chromatography screening showed no
evidence of inborn error of metabolism. Nerve conduction
velocity was normal, and electromyography did not show any
abnormalities. There was no homozygous deletion in exons 7
and 8 of the SMN1 (Survival of Motor Neuron 1) gene. The
possibility of a congenital myopathy emerged and muscle
biopsy was performed at the age of 4 years. Severe respiratory
tract infection and pneumonia led to respiratory failure, later
requiring tracheostomy and mechanical ventilation. His condi-
tion subsequently improved; however, he needs ventilatory
support during sleep. Cardiologic examination did not show
any abnormalities. The patient’s cognitive abilities were appro-
priate for his age.
The patient’s parents and his 3 siblings (a brother and 2
sisters) are asymptomatic.
Informed consent was requested from the parents prior to
the muscle biopsy and molecular genetic studies.
Muscle Biopsy
The histologic workup of the muscle biopsy tissue followed
standard procedures. The majority of the muscle fibers were
hypoplastic or atrophic with large variation in fiber size. Fiber
necrosis, regeneration, phagocytosis, or inflammatory cell infi-
ltration were not noted. Gomori’s trichrome technique detected
prominent red-stained inclusion bodies in the fibers with varia-
tion in number and distribution (Figure 1a). Toluidin blue-
stained sections showed rod-shaped particles in the fibers.
Electron microscopy revealed that the rods appeared as
electron-dense structures localized mainly along the thickened
Z-lines (Figure 1B). These rod-shaped particles were identified
as nemaline rods/bodies, and these findings were consistent
with the diagnosis of nemaline myopathy.
Genetics
In view of the morphologic findings, a search was initiated in
collaboration with the commercial diagnostic company Cento-
gene GmbH (Rostock, Germany) to find the molecular genetic
etiology of nemaline myopathy in this child. Tests for ACTA1
and TPM3 were negative. Eventual testing of the NEB gene
revealed 2 previously unreported heterozygous mutations: a
deletion (c.24527_24528delCT p.P8176fsX8179; Figure 2A)
in exon 174 and a duplication (c.24250_24253dupGTCA
p.T8085fsX8100; Figure 2B) in exon 171. These mutations
result in a frameshift and a premature termination codon,
respectively, presumably leading to truncated nebulin protein.
Further testing of the parents revealed that the father carries the
deletion and the mother has the heterozygous duplication
(Figure 3). One of the 2 sisters of the patient carries wild-
type alleles, whereas another sister and the brother are hetero-
zygous for the duplication (Figure 3). Thus, the clinically
unaffected family members carry either wild-type alleles or
only 1 of the mutant alleles; either the duplication or the dele-
tion. The patient, however, is a compound heterozygous carrier
of both mutations.
Discussion
Nemaline myopathies are a clinically and molecularly hetero-
geneous group of congenital myopathies.1-3 The combination
of characteristic clinical and histopathologic features are
Figure 1. Nemaline myopathy. (a) Toluidin blue staining of plastic-embedded semithin section shows numerous rod structures in the muscle
fibers. (b) Electron microscopy reveals that the rods are electron-dense structures.
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diagnostic for the disorder in most cases.1-3 The presence of red
inclusions detected with Gomori trichrome staining and of rod-
shaped particles in toluidine blue–stained tissue from the
patient strongly suggest nemaline myopathy.1-3 Ultrastructural
studies reveal nemaline bodies as electron-dense, rod-shaped
structures appearing as thickened Z-disks.1-3 Muscle imaging
by magnetic resonance can be helpful to visualize the pattern
of selective muscle involvement and guide in localizing the site
of the biopsy.7,8
The workup of a case with nemaline myopathy is further
complicated by its heterogeneous genetic background: 7 known
causative genes have been linked to this condition and both
autosomal dominant and recessive inheritance has been obser-
ved.2,9 Six of these genes encode proteins associated with sar-
comeric thin filaments.2 Recessive mutations in the NEB gene,
located on chromosome 2q22-23, are the most commonly
recognized cause of the disease.2,4 This gene has 182 exons,
and missense, nonsense, and frameshift mutations have been
reported.10 Hotspots have not been found and many patients
proved to be compound heterozygotes for 2 mutations within
the gene.2,10 The nebulin protein has a wide range of functions,
including thin filament length specification and regulation of
muscle contraction.4
The clinical, histologic, and molecular genetic findings in
our patient are consistent with the typical congenital form of
nemaline myopathy type 2, caused by mutations in the NEB
gene.2 Compound heterozygosity for 2 novel mutations was
Figure 2. Identification of 2 novel mutations (1 deletion and 1 duplication) in the NEB gene. Direct sequencing of DNA isolated from the
affected patient (II/4) revealed (A) a 2-base deletion (c.24527_24528delCT) in exon 174 of the NEB gene resulting in a premature termination
codon (p.P8176fsX8179) in the translated sequence and (B) a 4-base duplication (c.24250_24253dupGTCA) in exon 171 of theNEB gene, result-
ing in frameshift (p.T8085fsX8100) in the translated sequence.
Figure 3. Genetic screening of the affected family. The patient (II/4)
and his clinically unaffected father (I/1) carry the deletion in heterozy-
gous form, whereas the other unaffected family members (I/2, II/1, II/2,
II/3) carry the wild-type allele. The patient (II/4) and his clinically
unaffected mother (I/2), brother (II/2), and sister (II/3) carry the dupli-
cation in heterozygous form, whereas the other unaffected family
members (I/1, II/1) carry the wild-type allele. These results suggest
that the deletion is of paternal origin and the duplication is of maternal
origin. The patient (II/4) is, thus, a compound heterozygote for these 2
novel mutations.
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found. A 2-base deletion (c.24527_24528delCT, p.P8176fsX81-
79) was inherited from the father and a 4-base duplication
(c.24250_24253dupGTCA, p.T8085fsX8100) from the mother.
These novel mutations led to a translational frameshift and a pre-
mature termination codon in the respective translated sequences
and thus, presumably, to truncated nebulin protein.
Nemaline myopathy is a debilitating condition and further
research is warranted in order to explore the details of the mole-
cular pathology of this disorder. These efforts are complicated
by the heterogenic molecular background of the disease and the
fact that certain genes encode very large proteins like nebulin.
Molecular diagnosis, however, becomes available for more and
more patients supporting preimplantation or prenatal diagnosis
for subsequent pregnancies.2 This case report extends the
genetic profile of nemaline myopathy with 2 previously unre-
ported mutations in the NEB gene.
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ABSTRACT 
Introduction: Hereditary hyperekplexia (HKPX) is a neurological disorder characterized by 
excessive startle responses with violent jerking to noise or touch, stiffening of the trunk and 
limbs, clenching fists and attacks of a high-frequency trembling. Hyperekplexia has a 
heterogeneous genetic background with several identified causative genes and demonstrates both 
dominant and recessive inheritance. Mutations in the glycine receptor alpha 1 subunit gene 
(GLRA1) occur in about 30% of hyperekplexia cases.  
Case presentation: In this study, we report a Hungarian boy whose abnormal movements, 
muscle stiffness and convulsions were first noted when he was 4 days old. Neurological and 
electrophysiological investigation suggested the clinical diagnosis of hyperekplexia.  
Conclusions: Direct sequencing of the coding regions and the flanking introns of the GLRA1 
gene revealed a novel heterozygous missense mutation (c.211A/T, p.Ile71Phe). Genetic screening 
of the patient's family revealed that the clinically unaffected parents and sister do not carry the 
mutation suggesting that the identified sequence change is a de novo mutation. Since 
hyperekplexia can have severe consequences, including sudden infant death due to laryngospasm 
and cardiorespiratory failure, identification of the causative genetic alteration(s) of the disease is 
high priority. Such knowledge is necessary for prenatal diagnosis, which would allow informed 
family planning and greater parental sensitivity to hyperekplexia 1-associated risks.  
 
Key words: stiff-baby syndrome, hereditary hyperekplexia, GLRA1 gene, missense mutation 
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INTRODUCTION 
Hereditary hyperekplexia (HKPX, ORPHA3197) is an early-onset neurological disorder 
characterized by excessive startle responses with violent jerking to sudden, unexpected auditory 
or tactile stimuli [1,2]. Hyperekplexia usually develops shortly after birth: neonates have 
prolonged periods of stiffness, clenching fists and attacks of a high-frequency trembling [1,2]. 
Hyperekplexia can have severe consequences such as sudden infant death due to laryngospasm 
and cardiorespiratory failure [1]. The symptoms tend to resolve after infancy; however adults 
may have increased startle-induced falls or nocturnal muscle jerks [1].
 
Hyperekplexia has a heterogeneous genetic background [3,4]. Different mutations in several 
genes involved in glycinergic neurotransmission can lead to hyperekplexia, and the disease 
exhibits both autosomal recessive and dominant inheritance [3,4]. Mutations in the glycine 
receptor alpha 1 subunit gene (GLRA1) result in hyperekplexia 1 (OMIM149400) and occur in 
about 30% of hyperekplexia 1 cases [5]. Mutations in other genes such as the glycine receptor 
beta subunit gene (GLRB; HKPX2, OMIM614619) [6], the glycine transporter solute carrier 
family 6 member 5 gene (SLC6A5; HKPX3, OMIM614618) [7], the glycine receptor locator 
gephyrin gene (GPHN; OMIM603930) [8] and the postsynaptic glycine enhancer collybistin gene 
(ARHGEF9; OMIM300429) have also been associated with this clinical condition[9]. 
In this paper, we present the clinical and genetic investigations of a Hungarian family affected by 
hyperekplexia 1 and the identification of a novel disease-causing heterozygote missense mutation 
of the GLRA1 gene.  
 
CASE PRESENTATION 
A male neonate was born on term at the 40
th
 week of gestation by cesarean section delivery after 
an uneventful pregnancy. His birth weight was 3990 g and Apgar score was 9/10. At day 1 post-
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term, he developed pneumothorax and was admitted to the perinatal intensive care unit for extra 
oxygen and parenteral fluid therapy. At day 4 post-term, abnormal movements, stiffness of the 
muscles and convulsions were observed, and phenobarbital therapy was initiated. Neurological 
investigation suggested developmental disturbances of the basal moving circle. At day 11 post-
term, he was hospitalized in a developmental neurology ward. Examination did not identify 
hypoxia-induced regulatory abnormalities. The observed recurrent muscular hypertonia was 
attributed to a suspected ion channel disorder and carbamazepine therapy was initiated. 
Ultrasonography of the hip indicated the possibility of dysplasia on the left side, and 
ultrasonography of the abdomen revealed bilateral mild pyelectasis. The results of 
neurosonography, electroencephalography and magnetic resonance imaging of the head did not 
indicate any abnormalities of the central nervous system. 
After pre-test genetic counseling was performed and written informed consent was obtained from 
the parents, a blood sample was taken from the patient, his clinically unaffected sister and the 
clinically unaffected parents for genetic investigation. Genomic DNA was isolated using a 
BioRobot EZ1 DSP Workstation (QIAGEN; Hilden, Germany). The coding regions of the 
GLRA1 gene and the flanking introns were amplified and sequenced (using primers sequences 
obtained from the UCSC Genome Browser, www.genome.ucsc.edu). Molecular genetic 
investigation was carried out by the amplification and direct sequencing of the GLRA1 gene. 
Having identified the putative causative mutation in the patient (II/1), mutation screening of the 
unaffected family members (I/1, I/2 and II/1) was carried out. Direct sequencing of the coding 
regions and the flanking introns of the GLRA1 gene revealed a novel heterozygous missense 
mutation (c.211A/T, p.Ile71Phe) in exon 3 (Figure 1a). Mutation was confirmed by a second 
validation method, re-sequencing. Genetic screening of the affected family revealed that the 
clinically unaffected parents (I/1 and I/2) and the unaffected sister (II/1) did not carry the 
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mutation, suggesting that the identified novel sequence alteration is a de novo mutation in the 
patient (Figure 1d).  
 
CONCLUSIONS 
In this paper, we report a Hungarian patient with hyperekplexia, a potentially fatal neurological 
disorder characterized by pronounced startle responses. Abnormal movements, stiffness and 
convulsions were first noted in the patient at day 4 post-term, which correlates well with the 
early-onset of the disease. The initial severe symptoms of the patient were attenuated by 
carbamazepine therapy and physiotherapy and subsequently diminished with age.  
Hyperekplexia has been linked to genetic alterations in genes involved in an inhibitory 
neurotransmitter, glycine neurotransmission [3,4]. GLRA1 mutations account for approximately 
30% of all hyperekplexia cases [5]. Both compound heterozygous patients and homozygous 
mutation carriers have been described in the literature for recessive forms of the disease [10]. A 
heterozygous missense mutation (c.211A/T, p.Ile71Phe) was detected in the patient in exon 3 of 
the GLRA1 gene, establishing the diagnosis of hyperekplexia 1 and suggesting that the mutation 
is an autosomal dominant form of the disease. As the non-coding regions of the GLRA1 gene 
were not examined, we cannot exclude the possibility of second mutation that represents a 
recessive form in our patient. 
The GLRA1 gene encodes a neurotransmitter-gated ion channel transmembrane protein with three 
transmembrane segments (TM1–3) [11,12]. Binding of glycine to its receptor increases the 
chloride conductance, produces hyperpolarization and, thus, the inhibition of neuronal firing 
[11,12]. Previous studies have attributed dominant forms of hyperekplexia 1 to mutations within 
the pore-lining transmembrane segment (TM2) and adjacent regions, recessive forms to 
mutations within the other transmembrane segments (TM1 and TM3), and the null allele of the 
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GLRA1 gene to the deletion of exons 1–7 [11,12]. The novel heterozygous missense mutation 
(p.Ile71Phe) reported here is located close to the NH2-terminal of the GLRA1 protein outside the 
transmembrane segments (Figure 1b), in a highly conserved region (Figure 1c). The mutation is 
located in a region that is not predicted or known to be a functional domain of the GLRA1 
protein. Other missense mutations have been detected in this region in patients with 
hyperekplexia 1 (p.Trp68Cys and p.Arg72His) [3], and in spasmodic mouse (p.Ala52Ser) [13]. 
The functional analysis performed on the spasmodic mouse model suggested that the p.Ala52Ser 
missense mutation results in reduced glycine sensitivity [13]. Recessive mutations in the N-
terminal regions or majority of recessive hyperekplexia mutations have trafficking defects. 
Dominant mutations can may cause reduce glycine sensitivity. Based on these previous studies, 
we hypothesize that the reported novel missense mutation detected in our Hungarian patient 
might lead to reduced glycine sensitivity as well.  
It is also interesting to note, that previously reported missense mutations in this region (human 
p.Trp68Cys and p.Arg72His and murine p.Ala52Ser) are all associated with the recessive form of 
hyperekplexia 1, indicating the possibility that other undetected mutations might contribute to the 
clinical symptoms of our Hungarian patient. 
Having identified the putative causative mutation in the index patient, clinically unaffected 
family members were also screened and shown to carry only wildtype sequence of the GLRA1 
gene. Our results suggest that this novel missense sequence change (c.211A/T, p.Ile71Phe) 
identified in the index patient is a de novo mutation, however the vast majority of GLRA1 
mutations are inherited from parents in domimnant, recessive and compound heterizygote 
fashions [3,14,15]. 
The consequences of the hyperekplexia 1 can be severe, warranting further efforts to elucidate the 
nature of the disease despite the complications implicit with the heterogenic genetic background. 
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With the identification of the underlying genetic abnormalities, prenatal screening is available for 
affected families and allows informed family planning. In the future, knowledge of the genetic 
causes of this life-threatening disease may also contribute to the development of novel 
therapeutic alternatives. 
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FIGURE LEGENDS 
 
Figure 1. Identification of a novel mutation in the GLRA1 gene and genetic screening of the 
affected family. (a) Direct sequencing of patient (II/2) DNA revealed a novel heterozygous 
missense mutation in exon 3 of the GLRA1 gene. (b) The clinically unaffected family members 
(I/1, I/2 and II/1) carry only the wildtype sequence, suggesting a de novo mutation. (c) 
Comparison of GLRA1 protein sequences in the region of the mutation (p.Ile71Phe) from 
different species indicates that the region is highly conserved. (d) Genetic analysis of the affected 
family suggests that the identified sequence alteration is a de novo mutation. 
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